Journal article
Use of empiric antimicrobial therapy in neutropenic fever
CS Tam, M O'Reilly, D Andresen, S Lingaratnam, A Kelly, K Burbury, J Turnidge, MA Slavin, LJ Worth, L Dawson, KA Thursky
Internal Medicine Journal | WILEY | Published : 2011
Abstract
Administration of empiric antimicrobial therapy is standard practice in the management of neutropenic fever, but there remains considerable debate about the selection of an optimal regimen. In view of emerging evidence regarding efficacy and toxicity differences between empiric treatment regimens, and strong evidence of heterogeneity in clinical practice, the current guidelines were developed to provide Australian clinicians with comprehensive guidance for selecting an appropriate empiric strategy in the setting of neutropenic fever. Beta-lactam monotherapy is presented as the treatment of choice for all clinically stable patients while early treatment with combination antibiotic therapy is ..
View full abstractGrants
Funding Acknowledgements
Funding: These guidelines were developed independently through funding from Victorian Integrated Cancer Services. The Western and Central Melbourne Integrated Cancer Service (WCMICS), one of three metropolitan and five regional Integrated Cancer Services funded by the Victorian Department of Human Services to implement the Victorian Government's Cancer Services Framework across Victoria, administered this funding.Conflicts of interest: The following working group members are consultants or advisory committee members or receive honoraria, fees for service, or travel assistance (independent of research-related meetings) form; or have research or other associations with the organizations listed: Ian Davis - Novartis, Pfizer, GlaxoSmithKline, Schering-Plough; Andrew Grigg - Amgen, Gilead, Merck Sharp & Dohme, Novartis, Pfizer, Schering Plough, Sue Kirsa - Roche, Schering Plough, Amgen, Hospira, Alphapharm; Senthil Lingaratnam - Victorian Integrated Cancer Services; Orla Morrissey - Gilead, Merck Sharp & Dohme, Orphan, Pfizer, Schering Plough; William Renwick - Roche; Monica Slavin - Gilead, Merck Sharp & Dohme, Pfizer, Schering Plough; Brian Stein - Merck Serono; Constantine Tam - GSK, Roche; Karin Thursky - Gilead, Merck Sharp & Dohme, Pfizer, Schering Plough; Andrew Wei - Celgene, Hospira, Novartis.